Family Phenotypic Profile in Hereditary Hemorrhagic Telangiectasia: Genotype-Phenotype Correlation in the Pediatric Population

Family Phenotypic Profile in Hereditary Hemorrhagic Telangiectasia: Genotype-Phenotype Correlation in the Pediatric Population | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Family Phenotypic Profile in Hereditary Hemorrhagic Telangiectasia: Genotype-Phenotype Correlation in the Pediatric Population Valentina Giorgio, Chiara Di Foggia, Giovanna Quatrale, Gaia Margiotta, and 9 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4685890/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Hereditary Hemorrhagic Telangiectasia (HHT) is a rare, hereditary, autosomal dominant vascular disease, characterized by arteriovenous malformations (AVM), mucocutaneous telangiectasias and epistaxis. The management of pediatric patients is currently based on limited literature. The aim of our study is to evaluate whether the severity of HHT in affected children could be compared to their parents ‘phenotype, sharing the same genetic variants. We collected data about 11 pediatric patients and their parents with a confirmed diagnosis of HHT, from the medical records of Fondazione Policlinico Universitario A. Gemelli IRCCS (Rome, Italy). Starting from the analysis of the genotype-phenotype correlations among pediatric patients and their affected parents, we found that in three families (33,3%) the HHT presentation was similar between affected adults and affected siblings. In six families (67,7%) HHT phenotype was different between parents and children, being frequently more severe in parents rather than in children. Our results revealed a series of evidence confirming that HHT has variable phenotypic expressiveness. Hereditary Hemorrhagic Telangiectasia pediatrics genotype-phenotype correlation anemia ACVRL1 ENG HHT INTRODUCTION Hereditary Hemorrhagic Telangiectasia (HHT) or Rendu-Osler disease is a rare, hereditary, autosomal dominant vascular disease (overall prevalence between 1/5000 and 1/8000 individuals). It is characterized by abnormal angiogenesis leading to the development of arteriovenous malformations (AVM) and mucocutaneous telangiectasias, with epistaxis being the most frequent manifestation [ 1 – 5 ]. The management of pediatric patients, as outlined in the Second International Guidelines [ 6 ], is based on available literature [ 7 – 10 ] that presents the limits of a rare disease. According to expert panel, HHT pediatric patients should be tested for iron deficiency and anemia just in case of recurrent bleeding and/or symptoms of anemia, with hemoglobin targets individualized on patients (depending on symptoms, severity of HHT-related bleeding, previous iron supplementation, comorbidity). As regard to pulmonary AVMs, the expert panel recommends screening in children at the time of presentation and then every 5 years in asymptomatic patients; it may be performed with chest radiography and pulse oximetry or trans-thoracic contrast echocardiography, while lung CT remains a confirmatory test, if screening tests are positive. Large pulmonary AVMs (at least 3 mm in diameter) or AVMs causing hypoxemia are suitable for embolotherapy to avoid complications. Finally, brain VM should be screened at the time of presentation with MRI, representing the first-line screening to detect the presence of malformations and to determine the risk of hemorrhage. At the moment, there is no agreement if routinely screening for brain VMs asymptomatic children. Abdominal ultrasound for liver VMs screening is performed according to adult recommendations [ 6 ]. There is no data in current literature about a comparative analysis of phenotypic manifestations among patients belonging to the same family unit – i.e. sharing a common genotype. Therefore, the aim of our study is to determine, by describing the genotype-phenotype correlation in children with HHT and in their parents, whether HHT phenotypes are comparable among parents and affected children. METHODS We conducted a single-centre retrospective study on pediatric patients and their parents with a confirmed diagnosis of HHT. Data were collected between May 1, 2022, and May 31, 2023, from the medical records of Fondazione Policlinico Universitario A. Gemelli IRCCS (Rome, Italy). Affected parents of pediatric patients were asked to respond to a standardized semi-structured questionnaire, facilitating further investigation into the phenotypic manifestations of the pathology. Moreover, we conducted a standardized evaluation of all patients (including physical examination, medical history, laboratory and imaging tests performed) considering the following data: Clinical phenotype, investigated through the evaluation of the presence or absence of epistaxis, telangiectasias, AVM (pulmonary, hepatic, cerebral, gastrointestinal), and major bleeding (one of the following criterion: past treatment for bleeding and/or iron deficiency anemia – iron infusion/ blood transfusion); Hemoglobin, serum iron and ferritin values, analyzed for all pediatric and adult patients; Diagnostic tests -if performed-, such as ENT (ear-nose-throat) target examination, ultrasonography of the abdomen, MRI of the abdomen, brain MRI, chest CT scan, echocardiography with bubble test; Therapeutic interventions, such as iron infusions, laser ablation/cautery for epistaxis, embolizations, blood transfusions. For “subjects with a defined diagnosis of HHT,” we mean those who had confirmation of the pathology by genetic testing [ 11 ]. Data were analyzed using GraphPad PRISM 9. Comparable variables were analyzed using Student’s t test/one way ANOVA. A 0,05 level of significance was considered for all statistical tests. Editorial Policies and Ethical Considerations The study protocol was approved by Ethical Committee of Università Cattolica del Sacro Cuore di Roma. All patients and/or their parents/legal guardians signed informed consent form. Demographic and Clinical Characteristics The pediatric population [Table 1 ] consists of eleven children aged between 0 and 20 years, including 6 boys and 5 girls, with an average age of 11.82 ± 5.51 years, as shown. Two couple of sibs are included (child 1A-1B and child 4A-4B). All patients (100%) have a positive family history of HHT. The clinical history of 10 patients (90.9%) – 5 males and 5 females – is characterized by the presence of epistaxis. In 4 patients (36.4%) – 2 males and 2 females – mucocutaneous telangiectasias were found, while AVM are present in 3 patients (27.3%) – 2 males and 1 female. In particular, pulmonary AVM were diagnosed in 3 patients (27.3%), hepatic AVM in 1 (9.1%), cerebral AVM in 2 (18.2%). Table 1 Demographic and clinical characteristics of the population; statistically significant differences are marked with * Children Adults Mean age (years ± SD) 11,82 ± 5,51 47 ± 8,68 Sex (male/female ratio) 6/5 6/3 Epistaxis (N; %) 10/11; 90,9% 9/9; 100% Mucocutaneous telangiectasias (N; %) 4/11; 36,4% 9/9; * 100% Family history of HHT (N; %) 11/11; 100% 8/9; 88,9% AVM (N; %) 3/11; 27,3% 5/9; 55,6% Pulmonary AVM (N; %) 3/11; 27,3% 5/9; * 55,6% Hepatic AVM (N; %) 1/11; 9,1% 2/9; * 22,2% Cerebral AVM (N; %) 2/11; 18,2% 2/9; 22,2% The adult population [Table 1 ] – i.e. affected parents who share the same genetic variant as pediatric patients – consists of 9 patients, including six males and three females, with an average age of 47 ± 8.68 years. Of these, 8 patients (88.9%) have a positive family history of HHT. In all patients (100%), epistaxis was found. 9 (100%) patients present mucocutaneous telangiectasias, while AVM are described in 5 patients (55.6%). In particular, pulmonary AVM were diagnosed in 5 patients (55.6%), hepatic AVM in 2 (22.2%), cerebral AVM in 2 (22.2%). The diagnostic tests conducted in both populations are as follows: ENT the physical examination (the exam of nose, lips, oral cavity for telangiectases), performed in 10 out of 11 (90.9%) children and 8 out of 9 (88.9%) adults; Ultrasonography of the abdomen, conducted in 10 out of 11 (90.9%) children and in all 9 (100%) adults; MRI of the abdomen, conducted in 1 out of 11 (9.1%) children and in 1 out of 9 (11.1%) adults; Brain MRI, performed in 8 out of 11 (72.7%) children and 5 out of 9 (55.6%) adults; Chest CT scan, performed in 3 out of 11 (27.3%) children and 5 out of 9 (55.6%) adults, when screening tests were positive [ 6 ]; Echocardiography with bubble test, performed in 4 out of 11 (36.4%) children and in 3 out of 9 (33.3%) adults. Genetic Variants All patients, children, and adults, have a genetic diagnosis. In 11 children, 3 (27.3%) have a ENG gene variant, and 8 (72.7%) have ACVRL1 variants. In 9 adults, 3 (33.3%) have an ENG variant, and 6 (66.7%) have ACVRL1 variants. RESULTS Laboratory Values To assess the impact of bleeding on anemia and iron reserves, the following laboratory values were considered: hemoglobin, serum iron and ferritin. Within the pediatric population, no patient (0%) reported hemoglobin values below the cutoff [ 12 ]. In the adult population, 2 patients (22.2%) reported hemoglobin values below the cutoff [ 13 ]. No pediatric (0%) patient reported lower serum iron values than the cutoff [ 12 ]. 2 adult patients (22%) reported lower serum iron values than the cutoff [ 13 ]. No pediatric patient (0%) reported ferritin values below the cutoff [ 12 ]. 3 (33.3%) adult patients reported ferritin values below the cutoff [ 13 ]. Therapeutic Interventions Considering the therapeutic interventions (iron infusions, laser ablation/cautery for epistaxis, embolizations, blood transfusions) to which the pediatric population has been subjected, it appears that no child (0%) has ever needed transfusions for reasons related to HHT, while 2/11 children (18.2%) have had their AVM embolized. Considering the therapeutic interventions to which the adult population has been subjected, it appears that 1/9 adult (11.1%) has resorted to transfusions and 4/9 (44.4%) to iron infusions due to HHT-related anemia. 3/9 adults (33.3%) have also had their AVM embolized. Major Bleeding A comparison between the number of children and adults who have experienced major bleeding in the oral and nasal cavity shows that no child (0%) has experienced such bleeding, and 4 adults (44.4%) have required Emergency Room access for this reason. Genotype-Phenotype Correlation Table 2 illustrates genotype-phenotype correlations among pediatric patients and their affected parents, considering the following clinical data for evaluating phenotypic expression: Table 2 Genotype-phenotype correlation: child vs adult † Gene Variant AVMs (1/0) Treatments (1/0) Major bleedings (1/0) ACVRL1 c.1435C > T Family 1 Child 1A 0 0 0 Child 1B 0 0 0 Parent 1 0 0 0 c.200G > A Family 2 Child 2 0 0 0 Parent 2 0 1 (I) 1 c.526-6C > G Family 3 Child 3 0 0 0 Parent 3 1 (P-H-GI) 1 (I) 1 c.230G > A Family 4 Child 4A 1 (P-H-C) 0** 0 Child 4B 1 (P) 0*** 0 Parent 4 0 0 0 c.230G > A Family 5 Child 5 0 0 0 Parent 5 1 (H) 0 0 c.1120C > T Family 6 Child 6 0 0 0 Parent 6 0 0 0 ENG c.893del Family 7 Child 7 0 0 0 Parent 7 1 (P) 1 (T, I, E) 1 c.298del Family 8 Child 8 0 0 0 Parent 8 1 (P-H-C) 1 (E) 0 c.1A > G Family 9 Child 9 1 (P-C) 0 0 Parent 9 1 (P-C) 1 (E) 1 † Legend: • AVM: P = pulmonary; H = hepatic; C = cerebral; GI = gastrointestinal; • Treatments: T = transfusions due to HHT-related anemia; I = iron infusions due to HHT-related anemia; E = embolization. **: 1 iron infusion due to favism comorbidity ***: 1 blood trasfusion due to favism comorbidity Presence of AVM (pulmonary, hepatic, cerebral, gastrointestinal); Treatments necessitated by the severity of anemia and/or AVM (iron infusions, laser ablation/cautery for epistaxis, embolizations, blood transfusions); Major bleeding (one of the following criterion: past treatment for bleeding and/or iron deficiency anemia – iron infusion/ blood transfusion). It follows that: In family 1, with c.1435C > T variant in ACVRL1, no AVM, major treatments, or bleeding were recorded, neither in the parent nor in the two children. In family 2, with c.200G > A variant in ACVRL1, no AVM, major treatment or bleeding was recorded in the child, while iron infusions and major bleedings in the parent were recorded. In family 3, with c.526-6C > G variant in ACVRL1, no AVM, major treatments or bleeding was recorded in the child, while pulmonary, hepatic, and gastrointestinal AVMs, iron infusions, and major bleedings in the parent were recorded. In family 4, with c.230G > A variant in ACVRL1, no AVM, major treatment or bleeding was recorded in the parent, while pulmonary, hepatic, and cerebral AVMs were recorded in one child and pulmonary AVMs in the other. In family 5, with c.230G > A variant in ACVRL1, no AVM, major treatment or bleeding was recorded in the child, while hepatic AVMs were recorded in the parent. In family 6, with c.1120C > T variant in ACVRL1, no AVM, major treatment or bleeding was recorded, neither in the parent nor in the child. In family 7, with c.893del variant in ENG, no AVM, major treatment or bleeding was recorded in the child, while pulmonary AVMs, blood transfusions, iron infusions, embolizations and major bleedings in the parent were recorded. In family 8, with c.298del variant in ENG, no AVM, major treatment or bleeding was recorded in the child, while pulmonary, hepatic, and cerebral AVMs and embolizations in the parent were recorded. In family 9, with c.1A > G variant in ENG, pulmonary and cerebral AVMs were recorded in the child and pulmonary and cerebral AVMs, embolizations, and major bleedings were recorded in the parent. Also, Table 2 illustrates the distribution of pulmonary, hepatic and cerebral AVM in the pediatric and adult population in relation to the genotype (ACVRL1 or ENG variants). Out of a total of 8 children and 6 adults with ACVRL1 variants, 2 pediatric patients (25%) and 1 adult patient (16.7%) have pulmonary AVMs. Out of a total of 3 children and 3 adults with ENG variants, 1 pediatric patient (33.3%) and 3 adult patients (100%) have pulmonary AVMs. In 1 pediatric patient (12.5%) and no adult patient (0%) with ACVRL1 variants, cerebral AVM were found. Among patients with ENG variants, however, 1 child (33.3%) and 2 adults (66.7%) have cerebral AVMs. DISCUSSION Comparison with Literature The analysis of the phenotypes of the pediatric population examined revealed a series of evidence confirming the literature. 90.9% of patients have epistaxis, that is confirmed to be the first symptom to manifest itself during childhood, which, however, rarely requires cauterization or other significant interventions to control bleeding [ 9 ], as demonstrated by the absence of major bleedings (0%) in the target population. 36.4% of pediatric patients have mucocutaneous telangiectasias, which, when compared to the prevalence of those in the adult population (100%), has their later presentation confirmed [ 9 ]. The same applies to AVMs, present in 27.3% of pediatric patients and 55.6% of adult patients. The correlation of the phenotype characterized by the presence of pulmonary and cerebral AVMs with genotypes characterized by ENG and ACVRL1 variants is reported in Table 2 . The increased frequency of pulmonary and cerebral AVMs in patients - both pediatric and adult - with ENG variants has been confirmed, as reported in literature [ 8 ]. However, as evidenced by the presence of cerebral AVMs in 1 pediatric patient (12.5%) with a ACVRL1 variant, it must be reiterated that the genotype alone cannot and must not guide the screening practices, as different AVMs are potentially present in all genotypes [ 8 ]. Analysis of Laboratory Values Hemoglobin, serum iron, and ferritin below the respective cutoffs – as referred for age specific pediatric cut-off [ 12 ] - were not recorded for any pediatric patient. Moreover, none of these patients needed iron infusions or blood transfusions. These data strengthen published recommendations about blood test timeline both in adults and children with HHT [ 14 ]. An apparently normal value of hemoglobin in patients with pulmonary phenotype, as known, may depend on compensatory polycythemia. These patients, therefore, should be focused during the pubertal development period, due to the increase of iron requirement or increased loss – in post-menarche females. Genotype-Phenotype Correlation From the comparison of the phenotypes of the children with those of the parents with the same genotype (Table 2 ), despite the intrinsic limits linked to punctual considerations relative to a dynamic pathology, we have seen that, out of a total of 9 families analyzed, a similar clinical phenotype was recorded in 3 families (33.3%). In this regard, the case of family 4 deserves to be reported. The history of this family began in 2018 with the suspicion of HHT in the eldest son following the finding of hypoxemia (SpO2 85%) and multiple pulmonary AVMs, 2 of which were treated with embolization. Further diagnostic investigations were simultaneously carried out in the father and in the second child, and both were found to be affected by HHT with c.230G > A variant in ACVRL1 (shared by all three family members). It is interesting to note that, with the same clinical score (3) assigned through the Curaçao criteria, we were faced with extremely different clinical pictures. The firstborn (20 years) presented epistaxis and the so called “lung phenotype”. The second son (16 years old) also presented epistaxis, but more severe, and, in addition to pulmonary AVMs, a hepatic AVM and a cerebral AVM – i.e. a mixed phenotype. On the other hand, the father (58 years) presented only epistaxis - less severe than in the children - and meager telangiectasias. Therefore, the difference in the phenotypic expression of the disease is evident, as, while it has no impact, if not small, on the quality of life of the father, it has a great impact on that of both children. The story of this family can help reminding that intra-familial phenotypic variation is well-established; in fact, most disease-causing mutations in ACVRL1, ENG, and SMAD4 are null alleles that result in haploinsufficiency [ 15 ]. Clinicians dealing with families with HHT should keep this peculiarity in mind and eventually address it to the families. It is important to note that, in Italy, there is a National Health Care System providing a free screening and follow up program for rare diseases, including HHT. This program includes periodic abdominal ultrasound, that can be performed before the symptoms and/or signs of complications might appear. Our study has some limitations that need to be addressed. This is a single center study including few patients, with observational aims. It follows that, when possible, statistical analysis has been performed, but limited by the sample size. CONCLUSIONS The results obtained so far show that it is not possible to talk about the overlap of phenotypes between parents and children suffering from HHT, which is confirmed as a hereditary disease with variable expressiveness. We confirm that present guidelines are valuable and, since complications themselves may represent the onset manifestation in pediatric patients, an early diagnosis is indispensable for their prevention. Declarations Author Contribution GE, GV and DFC conceived the idea for this manuscript. DFC, GV, PGC and CA recruited patients and collected the data. DFC and GV wrote the manuscript, with additional critical feedback provided by GE. All authors reviewed and discussed the results and contributed to the final manuscript. Authorship Di Foggia C and Giorgio V should be considered joint first author Acknowledgements This work was supported by no funding sources. Conflict of interests All authors declare no conflicts of interest. Data Sharing and Data Accessibility The data that support the findings of this study are available from the corresponding author upon reasonable request. References Guttmacher A, Marchuck D, Pyeritz RE. Hereditary hemorrhagic telangiectasia. 5th ed. Philadelphia: Churchill Livingstone; 2007. McDonald J, Bayrak-Toydemir P, Pyeritz RE. Hereditary hemorrhagic telangiectasia: an overview of diagnosis, management, and pathogenesis. Genet Med. 2011;13(7):607–16. Sharathkumar AA, Shapiro A. Hereditary haemorrhagic telangiectasia. Haemophilia. 2008;14:1269–80. Guttmacher AE, Marchuk DA, White RI Jr.. Hereditary hemorrhagic telangiectasia. N Engl J Med. 1995;333:918–24. Govani F, Shovlin C. Hereditary haemorrhagic telangiectasia: a clinical and scientific review. Eur J Hum Gen. 2009;17:860–71. Faughnan ME, Mager JJ, Hetts SW, et al. Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia. Ann Intern Med. 2020;173(12):989–1001. 10.7326/M20-1443 . Epub 2020 Sep 8. PMID: 32894695. Kilian A, Latino GA, White AJ, et al. Genotype-Phenotype Correlations in Children with HHT. J Clin Med. 2020;9(9):2714. 10.3390/jcm9092714 . PMID: 32842615; PMCID: PMC7565052. Pahl KS, Choudhury A, Wusik K et al. Applicability of the Curaçao Criteria for the Diagnosis of Hereditary Hemorrhagic Telangiectasia in the Pediatric Population. J Pediatr. 2018;197:207–213. 10.1016/j.jpeds.2018.01.079 . Epub 2018 Apr 11. PMID: 29655863. Giordano P, Nigro A, Lenato GM et al. Screening for children from families with Rendu-Osler-Weber disease: from geneticist to clinician. J Thromb Haemost. 2006;4(6):1237-45. 10.1111/j.1538-7836.2006.01934.x . PMID: 16706966. Liu JR, Liu H, Wang B et al. Case report of hereditary hemorrhagic telangiectasia in children and literature review. Zhonghua Er Ke Za Zhi. 2020;58(8):674–678. Chinese. 10.3760/cma.j.cn112140-20200415-00386 . PMID: 32842389. McDonald J, Wooderchak-Donahue W, VanSant Webb C, et al. Hereditary hemorrhagic telangiectasia: genetics and molecular diagnostics in a new era. Front Genet. 2015;6:1. Jaquelyn M, Powers. Iron deficiency in infants and children < 12 years: Screening, prevention, clinical manifestations, and diagnosis, In:UpToDateaccessed on December 15, (2023). ABIM Laboratory. Test Reference Ranges ̶ July 2023. Kasthuri RS, Montifar M, Nelson J et al. Prevalence and predictors of anemia in hereditary hemorrhagic telangiectasia. Am J Hematol. 2017 Jun 22. Lenato GM, Guanti G. Hereditary Haemorrhagic Telangiectasia (HHT): genetic and molecular aspects. Curr Pharm Des. 2006;12(10):1173-93. 10.2174/138161206776361291 . PMID: 16611099. Additional Declarations No competing interests reported. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4685890","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":336598091,"identity":"655ac576-7e0b-4f7b-a5ab-1243e05f43f2","order_by":0,"name":"Valentina Giorgio","email":"","orcid":"","institution":"UOC di Pediatria, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore","correspondingAuthor":false,"prefix":"","firstName":"Valentina","middleName":"","lastName":"Giorgio","suffix":""},{"id":336598092,"identity":"4082baf0-90a8-4930-8377-feffb0f18036","order_by":1,"name":"Chiara Di Foggia","email":"","orcid":"","institution":"UOC di Pediatria, Dipartimento Materno Infantile e Scienze Urologiche, La Sapienza Università di Roma","correspondingAuthor":false,"prefix":"","firstName":"Chiara","middleName":"Di","lastName":"Foggia","suffix":""},{"id":336598093,"identity":"b9329928-6638-4175-89f8-33e384a860e6","order_by":2,"name":"Giovanna Quatrale","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAAyElEQVRIiWNgGAWjYNACAwY5PmYeMJOHGPWMDUAtxmwwLcToAWphYEhsg5lPUAvfjeTnD78U2KS3sfMefFxRwSBjT0iL5I00w2YZg7TcNma+ZMMzZ4hwmMGNBMNmCYPDQC08ZpKNbURpSf8I0pIO9L75TyK15Bg2fjA4nADUYsZIlBbJM28KZzMYpBmC/CLZcEaCh+cAAS18x9M3fPzxx0aen//swY8NFTb27A2ErAGayYzkFglC6iFaGH8QoW4UjIJRMApGMAAA+Js3KR2JqG8AAAAASUVORK5CYII=","orcid":"","institution":"Pediatric Unit, NESMOS Department, Faculty of Medicine \u0026 Psychology, Sapienza University of Rome, Sant’Andrea University Hospital, 00185 Rome, Italy","correspondingAuthor":true,"prefix":"","firstName":"Giovanna","middleName":"","lastName":"Quatrale","suffix":""},{"id":336598094,"identity":"f47a844f-53e0-4d99-9077-ff7e7971595f","order_by":3,"name":"Gaia Margiotta","email":"","orcid":"","institution":"UOC di Pediatria, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore","correspondingAuthor":false,"prefix":"","firstName":"Gaia","middleName":"","lastName":"Margiotta","suffix":""},{"id":336598095,"identity":"0eefb0c6-056d-4fc5-ab67-50724c27778b","order_by":4,"name":"Giuseppe Stella","email":"","orcid":"","institution":"UOC di Pediatria, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore","correspondingAuthor":false,"prefix":"","firstName":"Giuseppe","middleName":"","lastName":"Stella","suffix":""},{"id":336598096,"identity":"e8985e25-3a0b-443e-894a-7d1802d1d979","order_by":5,"name":"Francesco Proli","email":"","orcid":"","institution":"UOC di Pediatria, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore","correspondingAuthor":false,"prefix":"","firstName":"Francesco","middleName":"","lastName":"Proli","suffix":""},{"id":336598097,"identity":"a07f7635-0974-4bf6-813f-fc0226042b8d","order_by":6,"name":"Chiara Leoni","email":"","orcid":"","institution":"UOC di Pediatria, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore","correspondingAuthor":false,"prefix":"","firstName":"Chiara","middleName":"","lastName":"Leoni","suffix":""},{"id":336598098,"identity":"37d38b4e-e777-4c3e-8d93-79a4bff12d39","order_by":7,"name":"Roberta Onesimo","email":"","orcid":"","institution":"UOC di Pediatria, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore","correspondingAuthor":false,"prefix":"","firstName":"Roberta","middleName":"","lastName":"Onesimo","suffix":""},{"id":336598099,"identity":"78d21c78-c45e-42a5-bb44-0c5bd1585564","order_by":8,"name":"Giulio Cesare Passali","email":"","orcid":"","institution":"UOC di Otorinolaringoiatria, Dipartimento di Neuroscienze, Organi di Senso e Torace, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italia","correspondingAuthor":false,"prefix":"","firstName":"Giulio","middleName":"Cesare","lastName":"Passali","suffix":""},{"id":336598100,"identity":"bb92f9ca-5626-4d78-9452-5445c79e21df","order_by":9,"name":"Andrea Contegiacomo","email":"","orcid":"","institution":"Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore","correspondingAuthor":false,"prefix":"","firstName":"Andrea","middleName":"","lastName":"Contegiacomo","suffix":""},{"id":336598101,"identity":"2137c627-8c0d-4a6f-8c0c-cd8d89a7816e","order_by":10,"name":"Giuseppe Zampino","email":"","orcid":"","institution":"UOC di Pediatria, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore","correspondingAuthor":false,"prefix":"","firstName":"Giuseppe","middleName":"","lastName":"Zampino","suffix":""},{"id":336598102,"identity":"3c62772c-e907-4d49-a333-097d94176bf4","order_by":11,"name":"Antonio Gasbarrini","email":"","orcid":"","institution":"UOC di Medicina Interna e Gastroenterologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore","correspondingAuthor":false,"prefix":"","firstName":"Antonio","middleName":"","lastName":"Gasbarrini","suffix":""},{"id":336598103,"identity":"84d3dc62-5571-462f-a9ae-5e42b34f8a83","order_by":12,"name":"Eleonora Gaetani","email":"","orcid":"","institution":"UOC di Medicina Interna e Gastroenterologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore","correspondingAuthor":false,"prefix":"","firstName":"Eleonora","middleName":"","lastName":"Gaetani","suffix":""}],"badges":[],"createdAt":"2024-07-04 10:32:28","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-4685890/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4685890/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":66238024,"identity":"c4c73dc8-76f3-4137-9d9b-3d4dad409160","added_by":"auto","created_at":"2024-10-09 05:55:14","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":521576,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4685890/v1/b99e6437-c7d3-4e3f-be92-7bc071c53246.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Family Phenotypic Profile in Hereditary Hemorrhagic Telangiectasia: Genotype-Phenotype Correlation in the Pediatric Population","fulltext":[{"header":"INTRODUCTION","content":"\u003cp\u003eHereditary Hemorrhagic Telangiectasia (HHT) or Rendu-Osler disease is a rare, hereditary, autosomal dominant vascular disease (overall prevalence between 1/5000 and 1/8000 individuals). It is characterized by abnormal angiogenesis leading to the development of arteriovenous malformations (AVM) and mucocutaneous telangiectasias, with epistaxis being the most frequent manifestation [\u003cspan additionalcitationids=\"CR2 CR3 CR4\" citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eThe management of pediatric patients, as outlined in the Second International Guidelines [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e], is based on available literature [\u003cspan additionalcitationids=\"CR8 CR9\" citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e] that presents the limits of a rare disease. According to expert panel, HHT pediatric patients should be tested for iron deficiency and anemia just in case of recurrent bleeding and/or symptoms of anemia, with hemoglobin targets individualized on patients (depending on symptoms, severity of HHT-related bleeding, previous iron supplementation, comorbidity). As regard to pulmonary AVMs, the expert panel recommends screening in children at the time of presentation and then every 5 years in asymptomatic patients; it may be performed with chest radiography and pulse oximetry or trans-thoracic contrast echocardiography, while lung CT remains a confirmatory test, if screening tests are positive. Large pulmonary AVMs (at least 3 mm in diameter) or AVMs causing hypoxemia are suitable for embolotherapy to avoid complications. Finally, brain VM should be screened at the time of presentation with MRI, representing the first-line screening to detect the presence of malformations and to determine the risk of hemorrhage. At the moment, there is no agreement if routinely screening for brain VMs asymptomatic children. Abdominal ultrasound for liver VMs screening is performed according to adult recommendations [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eThere is no data in current literature about a comparative analysis of phenotypic manifestations among patients belonging to the same family unit \u0026ndash; i.e. sharing a common genotype.\u003c/p\u003e \u003cp\u003eTherefore, the aim of our study is to determine, by describing the genotype-phenotype correlation in children with HHT and in their parents, whether HHT phenotypes are comparable among parents and affected children.\u003c/p\u003e"},{"header":"METHODS","content":"\u003cp\u003eWe conducted a single-centre retrospective study on pediatric patients and their parents with a confirmed diagnosis of HHT. Data were collected between May 1, 2022, and May 31, 2023, from the medical records of Fondazione Policlinico Universitario A. Gemelli IRCCS (Rome, Italy).\u003c/p\u003e \u003cp\u003eAffected parents of pediatric patients were asked to respond to a standardized semi-structured questionnaire, facilitating further investigation into the phenotypic manifestations of the pathology.\u003c/p\u003e \u003cp\u003eMoreover, we conducted a standardized evaluation of all patients (including physical examination, medical history, laboratory and imaging tests performed) considering the following data:\u003c/p\u003e \u003cp\u003e \u003cul\u003e \u003cli\u003e \u003cp\u003eClinical phenotype, investigated through the evaluation of the presence or absence of epistaxis, telangiectasias, AVM (pulmonary, hepatic, cerebral, gastrointestinal), and major bleeding (one of the following criterion: past treatment for bleeding and/or iron deficiency anemia \u0026ndash; iron infusion/ blood transfusion);\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eHemoglobin, serum iron and ferritin values, analyzed for all pediatric and adult patients;\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eDiagnostic tests -if performed-, such as ENT (ear-nose-throat) target examination, ultrasonography of the abdomen, MRI of the abdomen, brain MRI, chest CT scan, echocardiography with bubble test;\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eTherapeutic interventions, such as iron infusions, laser ablation/cautery for epistaxis, embolizations, blood transfusions.\u003c/p\u003e \u003c/li\u003e \u003c/ul\u003e \u003c/p\u003e \u003cp\u003eFor \u0026ldquo;subjects with a defined diagnosis of HHT,\u0026rdquo; we mean those who had confirmation of the pathology by genetic testing [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eData were analyzed using GraphPad PRISM 9. Comparable variables were analyzed using Student\u0026rsquo;s t test/one way ANOVA. A 0,05 level of significance was considered for all statistical tests.\u003c/p\u003e \u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eEditorial Policies and Ethical Considerations\u003c/h2\u003e \u003cp\u003e The study protocol was approved by Ethical Committee of Universit\u0026agrave; Cattolica del Sacro Cuore di Roma. All patients and/or their parents/legal guardians signed informed consent form.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003eDemographic and Clinical Characteristics\u003c/h2\u003e \u003cp\u003eThe pediatric population [Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e] consists of eleven children aged between 0 and 20 years, including 6 boys and 5 girls, with an average age of 11.82\u0026thinsp;\u0026plusmn;\u0026thinsp;5.51 years, as shown. Two couple of sibs are included (child 1A-1B and child 4A-4B). All patients (100%) have a positive family history of HHT. The clinical history of 10 patients (90.9%) \u0026ndash; 5 males and 5 females \u0026ndash; is characterized by the presence of epistaxis. In 4 patients (36.4%) \u0026ndash; 2 males and 2 females \u0026ndash; mucocutaneous telangiectasias were found, while AVM are present in 3 patients (27.3%) \u0026ndash; 2 males and 1 female. In particular, pulmonary AVM were diagnosed in 3 patients (27.3%), hepatic AVM in 1 (9.1%), cerebral AVM in 2 (18.2%).\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eDemographic and clinical characteristics of the population; statistically significant differences are marked with *\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"3\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eChildren\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eAdults\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMean age (years\u0026thinsp;\u0026plusmn;\u0026thinsp;SD)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e11,82\u0026thinsp;\u0026plusmn;\u0026thinsp;5,51\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e47\u0026thinsp;\u0026plusmn;\u0026thinsp;8,68\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSex (male/female ratio)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e6/5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e6/3\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eEpistaxis (N; %)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e10/11;\u003c/p\u003e \u003cp\u003e90,9%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e9/9;\u003c/p\u003e \u003cp\u003e100%\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMucocutaneous telangiectasias (N; %)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e4/11;\u003c/p\u003e \u003cp\u003e36,4%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e9/9; *\u003c/p\u003e \u003cp\u003e100%\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eFamily history of HHT (N; %)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e11/11;\u003c/p\u003e \u003cp\u003e100%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e8/9;\u003c/p\u003e \u003cp\u003e88,9%\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAVM (N; %)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3/11;\u003c/p\u003e \u003cp\u003e27,3%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e5/9;\u003c/p\u003e \u003cp\u003e55,6%\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePulmonary AVM (N; %)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3/11;\u003c/p\u003e \u003cp\u003e27,3%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e5/9; *\u003c/p\u003e \u003cp\u003e55,6%\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHepatic AVM (N; %)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1/11;\u003c/p\u003e \u003cp\u003e9,1%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2/9; *\u003c/p\u003e \u003cp\u003e22,2%\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCerebral AVM (N; %)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2/11;\u003c/p\u003e \u003cp\u003e18,2%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2/9;\u003c/p\u003e \u003cp\u003e22,2%\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003eThe adult population [Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e] \u0026ndash; i.e. affected parents who share the same genetic variant as pediatric patients \u0026ndash; consists of 9 patients, including six males and three females, with an average age of 47\u0026thinsp;\u0026plusmn;\u0026thinsp;8.68 years. Of these, 8 patients (88.9%) have a positive family history of HHT. In all patients (100%), epistaxis was found. 9 (100%) patients present mucocutaneous telangiectasias, while AVM are described in 5 patients (55.6%). In particular, pulmonary AVM were diagnosed in 5 patients (55.6%), hepatic AVM in 2 (22.2%), cerebral AVM in 2 (22.2%).\u003c/p\u003e \u003cp\u003eThe diagnostic tests conducted in both populations are as follows:\u003c/p\u003e \u003cp\u003e\u003cul\u003e\u003cli\u003e\u003cp\u003e ENT the physical examination (the exam of nose, lips, oral cavity for telangiectases), performed in 10 out of 11 (90.9%) children and 8 out of 9 (88.9%) adults;\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003eUltrasonography of the abdomen, conducted in 10 out of 11 (90.9%) children and in all 9 (100%) adults;\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003eMRI of the abdomen, conducted in 1 out of 11 (9.1%) children and in 1 out of 9 (11.1%) adults;\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003eBrain MRI, performed in 8 out of 11 (72.7%) children and 5 out of 9 (55.6%) adults;\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003eChest CT scan, performed in 3 out of 11 (27.3%) children and 5 out of 9 (55.6%) adults, when screening tests were positive [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e];\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003eEchocardiography with bubble test, performed in 4 out of 11 (36.4%) children and in 3 out of 9 (33.3%) adults.\u003c/p\u003e\u003c/li\u003e\u003c/ul\u003e\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003eGenetic Variants\u003c/h2\u003e \u003cp\u003eAll patients, children, and adults, have a genetic diagnosis. In 11 children, 3 (27.3%) have a ENG gene variant, and 8 (72.7%) have ACVRL1 variants. In 9 adults, 3 (33.3%) have an ENG variant, and 6 (66.7%) have ACVRL1 variants.\u003c/p\u003e \u003c/div\u003e"},{"header":"RESULTS","content":"\u003cdiv id=\"Sec7\" class=\"Section2\"\u003e \u003ch2\u003eLaboratory Values\u003c/h2\u003e \u003cp\u003eTo assess the impact of bleeding on anemia and iron reserves, the following laboratory values were considered: hemoglobin, serum iron and ferritin.\u003c/p\u003e \u003cp\u003eWithin the pediatric population, no patient (0%) reported hemoglobin values below the cutoff [\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e]. In the adult population, 2 patients (22.2%) reported hemoglobin values below the cutoff [\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eNo pediatric (0%) patient reported lower serum iron values than the cutoff [\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e]. 2 adult patients (22%) reported lower serum iron values than the cutoff [\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eNo pediatric patient (0%) reported ferritin values below the cutoff [\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e]. 3 (33.3%) adult patients reported ferritin values below the cutoff [\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e].\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003eTherapeutic Interventions\u003c/h2\u003e \u003cp\u003eConsidering the therapeutic interventions (iron infusions, laser ablation/cautery for epistaxis, embolizations, blood transfusions) to which the pediatric population has been subjected, it appears that no child (0%) has ever needed transfusions for reasons related to HHT, while 2/11 children (18.2%) have had their AVM embolized.\u003c/p\u003e \u003cp\u003eConsidering the therapeutic interventions to which the adult population has been subjected, it appears that 1/9 adult (11.1%) has resorted to transfusions and 4/9 (44.4%) to iron infusions due to HHT-related anemia. 3/9 adults (33.3%) have also had their AVM embolized.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec9\" class=\"Section2\"\u003e \u003ch2\u003eMajor Bleeding\u003c/h2\u003e \u003cp\u003eA comparison between the number of children and adults who have experienced major bleeding in the oral and nasal cavity shows that no child (0%) has experienced such bleeding, and 4 adults (44.4%) have required Emergency Room access for this reason.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec10\" class=\"Section2\"\u003e \u003ch2\u003eGenotype-Phenotype Correlation\u003c/h2\u003e \u003cp\u003eTable\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e illustrates genotype-phenotype correlations among pediatric patients and their affected parents, considering the following clinical data for evaluating phenotypic expression:\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eGenotype-phenotype correlation: child vs adult\u003csup\u003e\u0026dagger;\u003c/sup\u003e\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"10\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c8\" colnum=\"8\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c9\" colnum=\"9\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c10\" colnum=\"10\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eGene\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003eVariant\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c6\"\u003e \u003cp\u003eAVMs\u003c/p\u003e \u003cp\u003e(1/0)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c8\" namest=\"c7\"\u003e \u003cp\u003eTreatments\u003c/p\u003e \u003cp\u003e(1/0)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c10\" namest=\"c9\"\u003e \u003cp\u003eMajor bleedings\u003c/p\u003e \u003cp\u003e(1/0)\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"13\" rowspan=\"14\"\u003e \u003cp\u003eACVRL1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" morerows=\"2\" nameend=\"c3\" namest=\"c2\" rowspan=\"3\"\u003e \u003cp\u003ec.1435C\u0026thinsp;\u0026gt;\u0026thinsp;T\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eFamily 1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eChild 1A\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c9\" namest=\"c8\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eChild 1B\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c9\" namest=\"c8\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eParent 1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c9\" namest=\"c8\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" morerows=\"1\" nameend=\"c3\" namest=\"c2\" rowspan=\"2\"\u003e \u003cp\u003ec.200G\u0026thinsp;\u0026gt;\u0026thinsp;A\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eFamily 2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eChild 2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c9\" namest=\"c8\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eParent 2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c9\" namest=\"c8\"\u003e \u003cp\u003e1\u003c/p\u003e \u003cp\u003e(I)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" morerows=\"1\" nameend=\"c3\" namest=\"c2\" rowspan=\"2\"\u003e \u003cp\u003ec.526-6C\u0026thinsp;\u0026gt;\u0026thinsp;G\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eFamily 3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eChild 3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c9\" namest=\"c8\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eParent 3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e1\u003c/p\u003e \u003cp\u003e(P-H-GI)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c9\" namest=\"c8\"\u003e \u003cp\u003e1\u003c/p\u003e \u003cp\u003e(I)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" morerows=\"2\" nameend=\"c3\" namest=\"c2\" rowspan=\"3\"\u003e \u003cp\u003ec.230G\u0026thinsp;\u0026gt;\u0026thinsp;A\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eFamily 4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eChild 4A\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e1\u003c/p\u003e \u003cp\u003e(P-H-C)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c9\" namest=\"c8\"\u003e \u003cp\u003e0**\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eChild 4B\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e1\u003c/p\u003e \u003cp\u003e(P)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c9\" namest=\"c8\"\u003e \u003cp\u003e0***\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eParent 4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c9\" namest=\"c8\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" morerows=\"1\" nameend=\"c3\" namest=\"c2\" rowspan=\"2\"\u003e \u003cp\u003ec.230G\u0026thinsp;\u0026gt;\u0026thinsp;A\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eFamily 5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eChild 5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c9\" namest=\"c8\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eParent 5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e1\u003c/p\u003e \u003cp\u003e(H)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c9\" namest=\"c8\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" morerows=\"1\" nameend=\"c3\" namest=\"c2\" rowspan=\"2\"\u003e \u003cp\u003ec.1120C\u0026thinsp;\u0026gt;\u0026thinsp;T\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eFamily 6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eChild 6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c9\" namest=\"c8\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eParent 6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c9\" namest=\"c8\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"5\" rowspan=\"6\"\u003e \u003cp\u003eENG\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" morerows=\"1\" nameend=\"c3\" namest=\"c2\" rowspan=\"2\"\u003e \u003cp\u003ec.893del\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eFamily 7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eChild 7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c9\" namest=\"c8\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eParent 7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e1\u003c/p\u003e \u003cp\u003e(P)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c9\" namest=\"c8\"\u003e \u003cp\u003e1\u003c/p\u003e \u003cp\u003e(T, I, E)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" morerows=\"1\" nameend=\"c3\" namest=\"c2\" rowspan=\"2\"\u003e \u003cp\u003ec.298del\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eFamily 8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eChild 8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c9\" namest=\"c8\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eParent 8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e1\u003c/p\u003e \u003cp\u003e(P-H-C)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c9\" namest=\"c8\"\u003e \u003cp\u003e1\u003c/p\u003e \u003cp\u003e(E)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" morerows=\"1\" nameend=\"c3\" namest=\"c2\" rowspan=\"2\"\u003e \u003cp\u003ec.1A\u0026thinsp;\u0026gt;\u0026thinsp;G\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eFamily 9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eChild 9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e1\u003c/p\u003e \u003cp\u003e(P-C)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c9\" namest=\"c8\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eParent 9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e1\u003c/p\u003e \u003cp\u003e(P-C)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c9\" namest=\"c8\"\u003e \u003cp\u003e1\u003c/p\u003e \u003cp\u003e(E)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"10\"\u003e\u003csup\u003e\u0026dagger;\u003c/sup\u003eLegend:\u003c/td\u003e\u003c/tr\u003e \u003ctr\u003e\u003ctd colspan=\"10\"\u003e\u0026bull; AVM: P\u0026thinsp;=\u0026thinsp;pulmonary; H\u0026thinsp;=\u0026thinsp;hepatic; C\u0026thinsp;=\u0026thinsp;cerebral; GI\u0026thinsp;=\u0026thinsp;gastrointestinal;\u003c/td\u003e\u003c/tr\u003e \u003ctr\u003e\u003ctd colspan=\"10\"\u003e\u0026bull; Treatments: T\u0026thinsp;=\u0026thinsp;transfusions due to HHT-related anemia; I\u0026thinsp;=\u0026thinsp;iron infusions due to HHT-related anemia; E\u0026thinsp;=\u0026thinsp;embolization.\u003c/td\u003e\u003c/tr\u003e \u003ctr\u003e\u003ctd colspan=\"10\"\u003e**: 1 iron infusion due to favism comorbidity\u003c/td\u003e\u003c/tr\u003e \u003ctr\u003e\u003ctd colspan=\"10\"\u003e***: 1 blood trasfusion due to favism comorbidity\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003cul\u003e \u003cli\u003e \u003cp\u003ePresence of AVM (pulmonary, hepatic, cerebral, gastrointestinal);\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eTreatments necessitated by the severity of anemia and/or AVM (iron infusions, laser ablation/cautery for epistaxis, embolizations, blood transfusions);\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eMajor bleeding (one of the following criterion: past treatment for bleeding and/or iron deficiency anemia \u0026ndash; iron infusion/ blood transfusion).\u003c/p\u003e \u003c/li\u003e \u003c/ul\u003e \u003c/p\u003e \u003cp\u003eIt follows that:\u003c/p\u003e \u003cp\u003e \u003cul\u003e \u003cli\u003e \u003cp\u003eIn family 1, with c.1435C\u0026thinsp;\u0026gt;\u0026thinsp;T variant in ACVRL1, no AVM, major treatments, or bleeding were recorded, neither in the parent nor in the two children.\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eIn family 2, with c.200G\u0026thinsp;\u0026gt;\u0026thinsp;A variant in ACVRL1, no AVM, major treatment or bleeding was recorded in the child, while iron infusions and major bleedings in the parent were recorded.\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eIn family 3, with c.526-6C\u0026thinsp;\u0026gt;\u0026thinsp;G variant in ACVRL1, no AVM, major treatments or bleeding was recorded in the child, while pulmonary, hepatic, and gastrointestinal AVMs, iron infusions, and major bleedings in the parent were recorded.\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eIn family 4, with c.230G\u0026thinsp;\u0026gt;\u0026thinsp;A variant in ACVRL1, no AVM, major treatment or bleeding was recorded in the parent, while pulmonary, hepatic, and cerebral AVMs were recorded in one child and pulmonary AVMs in the other.\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eIn family 5, with c.230G\u0026thinsp;\u0026gt;\u0026thinsp;A variant in ACVRL1, no AVM, major treatment or bleeding was recorded in the child, while hepatic AVMs were recorded in the parent.\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eIn family 6, with c.1120C\u0026thinsp;\u0026gt;\u0026thinsp;T variant in ACVRL1, no AVM, major treatment or bleeding was recorded, neither in the parent nor in the child.\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eIn family 7, with c.893del variant in ENG, no AVM, major treatment or bleeding was recorded in the child, while pulmonary AVMs, blood transfusions, iron infusions, embolizations and major bleedings in the parent were recorded.\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eIn family 8, with c.298del variant in ENG, no AVM, major treatment or bleeding was recorded in the child, while pulmonary, hepatic, and cerebral AVMs and embolizations in the parent were recorded.\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eIn family 9, with c.1A\u0026thinsp;\u0026gt;\u0026thinsp;G variant in ENG, pulmonary and cerebral AVMs were recorded in the child and pulmonary and cerebral AVMs, embolizations, and major bleedings were recorded in the parent.\u003c/p\u003e \u003c/li\u003e \u003c/ul\u003e \u003c/p\u003e \u003cp\u003eAlso, Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e illustrates the distribution of pulmonary, hepatic and cerebral AVM in the pediatric and adult population in relation to the genotype (ACVRL1 or ENG variants).\u003c/p\u003e \u003cp\u003eOut of a total of 8 children and 6 adults with ACVRL1 variants, 2 pediatric patients (25%) and 1 adult patient (16.7%) have pulmonary AVMs.\u003c/p\u003e \u003cp\u003eOut of a total of 3 children and 3 adults with ENG variants, 1 pediatric patient (33.3%) and 3 adult patients (100%) have pulmonary AVMs.\u003c/p\u003e \u003cp\u003eIn 1 pediatric patient (12.5%) and no adult patient (0%) with ACVRL1 variants, cerebral AVM were found. Among patients with ENG variants, however, 1 child (33.3%) and 2 adults (66.7%) have cerebral AVMs.\u003c/p\u003e \u003c/div\u003e"},{"header":"DISCUSSION","content":"\u003cdiv id=\"Sec12\" class=\"Section2\"\u003e \u003ch2\u003eComparison with Literature\u003c/h2\u003e \u003cp\u003eThe analysis of the phenotypes of the pediatric population examined revealed a series of evidence confirming the literature. 90.9% of patients have epistaxis, that is confirmed to be the first symptom to manifest itself during childhood, which, however, rarely requires cauterization or other significant interventions to control bleeding [\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e], as demonstrated by the absence of major bleedings (0%) in the target population.\u003c/p\u003e \u003cp\u003e36.4% of pediatric patients have mucocutaneous telangiectasias, which, when compared to the prevalence of those in the adult population (100%), has their later presentation confirmed [\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e]. The same applies to AVMs, present in 27.3% of pediatric patients and 55.6% of adult patients.\u003c/p\u003e \u003cp\u003eThe correlation of the phenotype characterized by the presence of pulmonary and cerebral AVMs with genotypes characterized by ENG and ACVRL1 variants is reported in Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e. The increased frequency of pulmonary and cerebral AVMs in patients - both pediatric and adult - with ENG variants has been confirmed, as reported in literature [\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]. However, as evidenced by the presence of cerebral AVMs in 1 pediatric patient (12.5%) with a ACVRL1 variant, it must be reiterated that the genotype alone cannot and must not guide the screening practices, as different AVMs are potentially present in all genotypes [\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e].\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec13\" class=\"Section2\"\u003e \u003ch2\u003eAnalysis of Laboratory Values\u003c/h2\u003e \u003cp\u003eHemoglobin, serum iron, and ferritin below the respective cutoffs \u0026ndash; as referred for age specific pediatric cut-off [\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e] - were not recorded for any pediatric patient. Moreover, none of these patients needed iron infusions or blood transfusions. These data strengthen published recommendations about blood test timeline both in adults and children with HHT [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e]. An apparently normal value of hemoglobin in patients with pulmonary phenotype, as known, may depend on compensatory polycythemia. These patients, therefore, should be focused during the pubertal development period, due to the increase of iron requirement or increased loss \u0026ndash; in post-menarche females.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec14\" class=\"Section2\"\u003e \u003ch2\u003eGenotype-Phenotype Correlation\u003c/h2\u003e \u003cp\u003eFrom the comparison of the phenotypes of the children with those of the parents with the same genotype (Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e), despite the intrinsic limits linked to punctual considerations relative to a dynamic pathology, we have seen that, out of a total of 9 families analyzed, a similar clinical phenotype was recorded in 3 families (33.3%).\u003c/p\u003e \u003cp\u003eIn this regard, the case of family 4 deserves to be reported. The history of this family began in 2018 with the suspicion of HHT in the eldest son following the finding of hypoxemia (SpO2 85%) and multiple pulmonary AVMs, 2 of which were treated with embolization. Further diagnostic investigations were simultaneously carried out in the father and in the second child, and both were found to be affected by HHT with c.230G\u0026thinsp;\u0026gt;\u0026thinsp;A variant in ACVRL1 (shared by all three family members). It is interesting to note that, with the same clinical score (3) assigned through the Cura\u0026ccedil;ao criteria, we were faced with extremely different clinical pictures. The firstborn (20 years) presented epistaxis and the so called \u0026ldquo;lung phenotype\u0026rdquo;. The second son (16 years old) also presented epistaxis, but more severe, and, in addition to pulmonary AVMs, a hepatic AVM and a cerebral AVM \u0026ndash; i.e. a mixed phenotype. On the other hand, the father (58 years) presented only epistaxis - less severe than in the children - and meager telangiectasias. Therefore, the difference in the phenotypic expression of the disease is evident, as, while it has no impact, if not small, on the quality of life of the father, it has a great impact on that of both children. The story of this family can help reminding that intra-familial phenotypic variation is well-established; in fact, most disease-causing mutations in ACVRL1, ENG, and SMAD4 are null alleles that result in haploinsufficiency [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e]. Clinicians dealing with families with HHT should keep this peculiarity in mind and eventually address it to the families.\u003c/p\u003e \u003cp\u003eIt is important to note that, in Italy, there is a National Health Care System providing a free screening and follow up program for rare diseases, including HHT. This program includes periodic abdominal ultrasound, that can be performed before the symptoms and/or signs of complications might appear.\u003c/p\u003e \u003cp\u003eOur study has some limitations that need to be addressed. This is a single center study including few patients, with observational aims. It follows that, when possible, statistical analysis has been performed, but limited by the sample size.\u003c/p\u003e \u003c/div\u003e"},{"header":"CONCLUSIONS","content":"\u003cp\u003eThe results obtained so far show that it is not possible to talk about the overlap of phenotypes between parents and children suffering from HHT, which is confirmed as a hereditary disease with variable expressiveness. We confirm that present guidelines are valuable and, since complications themselves may represent the onset manifestation in pediatric patients, an early diagnosis is indispensable for their prevention.\u003c/p\u003e"},{"header":"Declarations","content":"\u003ch2\u003eAuthor Contribution\u003c/h2\u003e\u003cp\u003eGE, GV and DFC conceived the idea for this manuscript. DFC, GV, PGC and CA recruited patients and collected the data. DFC and GV wrote the manuscript, with additional critical feedback provided by GE. All authors reviewed and discussed the results and contributed to the final manuscript.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eAuthorship\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eDi Foggia C and Giorgio V should be considered joint first author\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAcknowledgements\u003c/strong\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThis work was supported by no funding sources.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConflict of interests\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll authors declare no conflicts of interest.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eData Sharing and Data Accessibility\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe data that support the findings of this study are available from the corresponding author upon reasonable request.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eGuttmacher A, Marchuck D, Pyeritz RE. Hereditary hemorrhagic telangiectasia. 5th ed. Philadelphia: Churchill Livingstone; 2007.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMcDonald J, Bayrak-Toydemir P, Pyeritz RE. Hereditary hemorrhagic telangiectasia: an overview of diagnosis, management, and pathogenesis. Genet Med. 2011;13(7):607\u0026ndash;16.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSharathkumar AA, Shapiro A. Hereditary haemorrhagic telangiectasia. Haemophilia. 2008;14:1269\u0026ndash;80.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGuttmacher AE, Marchuk DA, White RI Jr.. Hereditary hemorrhagic telangiectasia. N Engl J Med. 1995;333:918\u0026ndash;24.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGovani F, Shovlin C. Hereditary haemorrhagic telangiectasia: a clinical and scientific review. Eur J Hum Gen. 2009;17:860\u0026ndash;71.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFaughnan ME, Mager JJ, Hetts SW, et al. Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia. Ann Intern Med. 2020;173(12):989\u0026ndash;1001. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.7326/M20-1443\u003c/span\u003e\u003cspan address=\"10.7326/M20-1443\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e. Epub 2020 Sep 8. PMID: 32894695.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKilian A, Latino GA, White AJ, et al. Genotype-Phenotype Correlations in Children with HHT. J Clin Med. 2020;9(9):2714. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3390/jcm9092714\u003c/span\u003e\u003cspan address=\"10.3390/jcm9092714\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e. PMID: 32842615; PMCID: PMC7565052.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePahl KS, Choudhury A, Wusik K et al. Applicability of the Cura\u0026ccedil;ao Criteria for the Diagnosis of Hereditary Hemorrhagic Telangiectasia in the Pediatric Population. J Pediatr. 2018;197:207\u0026ndash;213. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.jpeds.2018.01.079\u003c/span\u003e\u003cspan address=\"10.1016/j.jpeds.2018.01.079\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e. Epub 2018 Apr 11. PMID: 29655863.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGiordano P, Nigro A, Lenato GM et al. Screening for children from families with Rendu-Osler-Weber disease: from geneticist to clinician. J Thromb Haemost. 2006;4(6):1237-45. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1111/j.1538-7836.2006.01934.x\u003c/span\u003e\u003cspan address=\"10.1111/j.1538-7836.2006.01934.x\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e. PMID: 16706966.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLiu JR, Liu H, Wang B et al. Case report of hereditary hemorrhagic telangiectasia in children and literature review. Zhonghua Er Ke Za Zhi. 2020;58(8):674\u0026ndash;678. Chinese. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3760/cma.j.cn112140-20200415-00386\u003c/span\u003e\u003cspan address=\"10.3760/cma.j.cn112140-20200415-00386\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e. PMID: 32842389.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMcDonald J, Wooderchak-Donahue W, VanSant Webb C, et al. Hereditary hemorrhagic telangiectasia: genetics and molecular diagnostics in a new era. Front Genet. 2015;6:1.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eJaquelyn M, Powers. Iron deficiency in infants and children\u0026thinsp;\u0026lt;\u0026thinsp;12 years: Screening, prevention, clinical manifestations, and diagnosis, In:UpToDateaccessed on December 15, (2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eABIM Laboratory. Test Reference Ranges ̶ July 2023.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKasthuri RS, Montifar M, Nelson J et al. Prevalence and predictors of anemia in hereditary hemorrhagic telangiectasia. Am J Hematol. 2017 Jun 22.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLenato GM, Guanti G. Hereditary Haemorrhagic Telangiectasia (HHT): genetic and molecular aspects. Curr Pharm Des. 2006;12(10):1173-93. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.2174/138161206776361291\u003c/span\u003e\u003cspan address=\"10.2174/138161206776361291\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e. PMID: 16611099.\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Hereditary Hemorrhagic Telangiectasia, pediatrics, genotype-phenotype correlation, anemia, ACVRL1, ENG, HHT","lastPublishedDoi":"10.21203/rs.3.rs-4685890/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4685890/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eHereditary Hemorrhagic Telangiectasia (HHT) is a rare, hereditary, autosomal dominant vascular disease, characterized by arteriovenous malformations (AVM), mucocutaneous telangiectasias and epistaxis.\u003c/p\u003e \u003cp\u003eThe management of pediatric patients is currently based on limited literature.\u003c/p\u003e \u003cp\u003eThe aim of our study is to evaluate whether the severity of HHT in affected children could be compared to their parents \u0026lsquo;phenotype, sharing the same genetic variants.\u003c/p\u003e \u003cp\u003e We collected data about 11 pediatric patients and their parents with a confirmed diagnosis of HHT, from the medical records of Fondazione Policlinico Universitario A. Gemelli IRCCS (Rome, Italy).\u003c/p\u003e \u003cp\u003eStarting from the analysis of the genotype-phenotype correlations among pediatric patients and their affected parents, we found that in three families (33,3%) the HHT presentation was similar between affected adults and affected siblings. In six families (67,7%) HHT phenotype was different between parents and children, being frequently more severe in parents rather than in children. Our results revealed a series of evidence confirming that HHT has variable phenotypic expressiveness.\u003c/p\u003e","manuscriptTitle":"Family Phenotypic Profile in Hereditary Hemorrhagic Telangiectasia: Genotype-Phenotype Correlation in the Pediatric Population","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-08-07 03:33:41","doi":"10.21203/rs.3.rs-4685890/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"36290c7f-6166-4700-aa39-dd3ba5d1456c","owner":[],"postedDate":"August 7th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2024-10-09T05:55:04+00:00","versionOfRecord":[],"versionCreatedAt":"2024-08-07 03:33:41","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-4685890","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4685890","identity":"rs-4685890","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}